Matched pair antibody available for Hydrocortisone [BSA]: Hydrocortisone antibody (Catalog # HMABPY027)
Format
Liquid
Concentration
Batch dependent - please inquire should you have specific requirements.
Buffer
0.01M pH7.4 PBS
Preservative
None
Storage
Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
Keywords
Cobadex;hydrocortisone
Citations
Publication ()
Have you cited DAGA-024B in a publication? Let us know and earn a reward for your research.
Background
Hydrocortisone, also known as cortisol, is a synthetic or pharmaceutical form of the hormone cortisol. It belongs to the class of corticosteroids, specifically glucocorticoids and mineralocorticoids. Hydrocortisone is widely used in medicine due to its potent anti-inflammatory and immunosuppressive properties. The hormone cortisol is naturally produced in the adrenal glands, which are located on top of the kidneys. It plays a crucial role in regulating various physiological processes in the body, including metabolism, immune response, stress response, and maintenance of blood pressure and electrolyte balance. Cortisol helps the body respond to stress by increasing blood sugar levels and suppressing the immune system.
Hydrocortisone is primarily used as a medication to treat a wide range of medical conditions. It is commonly prescribed for adrenocortical insufficiency, a condition where the adrenal glands do not produce enough cortisol. Hydrocortisone is considered the treatment of choice for this condition, and it helps to replace deficient cortisol levels. In addition, hydrocortisone is used in the management of various inflammatory and autoimmune conditions. It is prescribed for conditions like rheumatoid arthritis, asthma, dermatitis, and certain allergic reactions. Topical forms of hydrocortisone, such as creams and ointments, are also available for the treatment of skin conditions like eczema, psoriasis, and allergic rashes.
The pharmacology of hydrocortisone involves its interaction with specific receptors in the body. It binds to glucocorticoid receptors, leading to the suppression of inflammation and immune responses. It also exhibits mineralocorticoid activity, which helps regulate electrolyte and water balance. It is important to note that hydrocortisone, like other corticosteroids, can have significant side effects, particularly when used long-term or at high doses. These side effects include mood changes, an increased risk of infections, osteoporosis, gastrointestinal issues, and adrenal suppression.
Creative Diagnostics products are for RESEARCH USE ONLY, please make sure your review is research based.
Required fields are marked with *
Terms and conditions:
We will select high-quality review customers and offer a $30 coupon for your next purchase.
All product reviews must be submitted in the English language.
Creative Diagnostics will not share any personal information of applicants, and all information will be treated with strict confidentiality and will not be sold or disclosed to a third party.
References
Hydrocortisone therapy for patients with multiple trauma: the randomized controlled HYPOLYTE study
Jama
Authors: Roquilly, A., Mahe, P. J., Seguin, P., Guitton, C., Floch, H., Tellier, A. C., Asehnoune, K.
Context The role of stress-dose hydrocortisone in the management of trauma patients is currently unknown. Objective To test the efficacy of hydrocortisone therapy in trauma patients. Design, Setting, and Patients Multicenter, randomized, double-blind, placebo-controlled HYPOLYTE (Hydrocortisone Polytraumatise) study. From November 2006 to August 2009, 150 patients with severe trauma were included in 7 intensive care units in France. Intervention Patients were randomly assigned to a continuous intravenous infusion of either hydrocortisone (200 mg/d for 5 days, followed by 100 mg on day 6 and 50 mg on day 7) or placebo. The treatment was stopped if patients had an appropriate adrenal response. Main Outcome Measure Hospital-acquired pneumonia within 28 days. Secondary outcomes included the duration of mechanical ventilation, hyponatremia, and death. Results One patient withdrew consent. An intention-to-treat (ITT) analysis included the 149 patients, a modified ITT analysis included 113 patients with corticosteroid insufficiency. In the ITT analysis, 26 of 73 patients (35.6%) treated with hydrocortisone and 39 of 76 patients (51.3%) receiving placebo developed hospital-acquired pneumonia by day 28 (hazard ratio [HR], 0.51; 95% confidence interval [CI], 0.30-0.83; P = .007). In the modified ITT analysis, 20 of 56 patients (35.7%) in the hydrocortisone group and 31 of 57 patients (54.4%) in the placebo group developed hospital-acquired pneumonia by day 28 (HR, 0.47; 95% CI, 0.25-0.86; P = .01). Mechanical ventilation–free days increased with hydrocortisone by 4 days (95% CI, 2-7; P = .001) in the ITT analysis and 6 days (95% CI, 2-11; P < .001) in the modified ITT analysis. Hyponatremia was observed in 7 of 76 (9.2%) in the placebo group vs none in the hydrocortisone group (absolute difference, ?9%; 95% CI, ?16% to ?3%; P = .01). Four of 76 patients (5.3%) in the placebo group and 6 of 73 (8.2%) in the hydrocortisone group died (absolute difference, 3%; 95% CI, ?5% to 11%; P = .44). Conclusion In intubated trauma patients, the use of an intravenous stress-dose of hydrocortisone, compared with placebo, resulted in a decreased risk of hospital-acquired pneumonia.
Acute effects of hydrocortisone on the human brain: An fMRI study
Psychoneuroendocrinology
Authors: Lovallo, W. R., Robinson, J. L., Glahn, D. C., Fox, P. T.
Cortisol is essential for regulating all cell types in the body, including those in the brain. Most information concerning cortisol's cerebral effects comes from work in nonhumans. This is a first effort to use functional magnetic resonance imaging (fMRI) to study the time course and locus of cortisol's effects on selected brain structures in resting humans. We repeatedly scanned 21 healthy young adults over 45 min to examine changes in the brain's activity 5 min before, and for 40 min after, an IV injection of 10 mg of hydrocortisone (N = 11) or saline placebo (N = 10). At 15–18 min postinjection we observed in the hydrocortisone group reduced activity in the hippocampus and amygdala that reached a peak response minimum at 25–30 min postinjection (?1 Standard Deviation) relative to placebo. No such effect was seen in the thalamus. Functional MRI appears to be a safe, noninvasive method to study the time course and anatomical effects of glucocorticoids in the human brain.
COA
Publication 
Loading ......
